Elliott Sigal

Senior Advisor to the healthcare team of New Enterprise Associates; former Executive Vice President and Director of Bristol-Myers Squibb, where he also served as Chief Scientific officer and President of R&D; Co-chair of the Scientific Advisory Board of Amgen; Member of Scientific Steering Committee for the Sean Parker Institute for Cancer Immunotherapy and member of the Board of Directors for Adaptimmune, Vir Biotechnology and Surface Oncology.